• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 14, 2013

View Archived Issues

Earnouts and Back-Ended Deals Expected to Continue

SAN DIEGO – At a Calbio session, Cambell Alliance, the business consulting segment of Inventiv Health Inc., presented its survey of business development professionals. Read More

Protein Folds: Simpler than Current, Complex Notions?

Predicting protein folding has made strides in recent years, mainly through unconventional approaches. Computer games like foldit have been able to apply crowdsourcing to proteins, and solve structures that had evaded traditional computing power. Read More

'Tea'-ing Off in China? Celgene Shares Lessons from Hot Market

For Celgene Corp., entering Japan proved a relatively brisk venture, said Jerome Zeldis, the company's chief medical officer, but China – where Celgene also has established itself, and is launching Revlimid (lenalidomide) this week – represents something more of a challenge for biotech and pharma firms. Read More

Takeda, Sea Lane Shake Hands On Two-Year Technology Deal

Takeda California Inc., of San Diego, a subsidiary of Takeda Pharmaceutical Co. Ltd., partnered with Sea Lane Biotechnologies, of Mountain View, Calif., giving Takeda access to Sea Lane's Concirt human antibody libraries for its drug discovery program in exchange for an up-front payment and milestone option fees for projects initiated under the collaboration. Read More

Financings Roundup

• Esperion Therapeutics Inc., of Plymouth, Mich., filed terms for its initial public offering, planning to raise $63 million by offering 4.5 million shares at a price range of $13 to $15. Read More

Other News To Note

• Cornerstone Therapeutics Inc., of Cary, N.C., said it received on June 11 a Paragraph IV notice letter from Exela Pharma Sciences LLC, of Lenoir, N.C., advising the firm of Exela's filing of a supplemental new drug application for use of an injectable form of nicardipine hydrochloride in 9 percent sodium chloride, a generic version of Cornerstone's Cardene I.V. premixed injection. Read More

Stock Movers

Read More

Clinic Roundup

• Immunomedics Inc., of Morris Plains, N.J., said UCB SA, of Brussels, Belgium, reported new data from a Phase IIb open-label extension study of epratuzumab for systemic lupus erythematosus showing no new safety or tolerability signals, plus reduction in disease activity maintained over two years. Secondary outcome data also showed that compared to baseline values, treatment for two years with epratuzumab was associated in lower corticosteroid use. Read More

Pharma: Other News To Note

• Astrazeneca plc, of London, the University of Manchester and Cancer Research Technology, the commercial arm of Cancer Research UK, inked two agreements to seek new cancer drugs. Read More

Pharma: Clinic Roundup

• Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase III study published in The Lancet showed patients with active psoriatic arthritis who received either Stelara (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint, compared to patients receiving placebo. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe